Investment Rating - The report gives an "Accumulate" rating for the company, marking the first coverage [4]. Core Insights - The company has abundant cash reserves of 4.01 billion yuan and trading financial assets of 1.06 billion yuan, with a low debt ratio of 4.24%, providing solid support for innovation and development [2][33]. - The company is focusing on its core human vaccine business while extending its vision to innovative drugs and therapies, actively exploring investment and acquisition opportunities in the biopharmaceutical sector [2][33]. - The management is closely monitoring market dynamics and is committed to selecting new projects and businesses with investment value and growth potential to create a second growth curve for the company [2][33]. Financial Forecast and Valuation - The company is expected to achieve operating revenues of 1.348 billion, 1.418 billion, and 1.530 billion yuan from 2025 to 2027, with net profits of 200 million, 223 million, and 254 million yuan respectively, leading to EPS of 0.48, 0.53, and 0.61 yuan [2][41]. - The stock price corresponds to a PE ratio of 55 times for 2025 [2][41]. Company Overview - The company, established in 2002, is a leader in the domestic rabies vaccine market and the only provider of inactivated Japanese encephalitis vaccine in China, maintaining a leading market share since 2008 [13][27]. - The company has faced revenue fluctuations due to intensified competition in the domestic vaccine market, particularly affecting rabies vaccine sales [15][27]. - The company has maintained high R&D investment levels, which have impacted profits but have also led to a robust pipeline of products entering late-stage clinical trials [24][27]. Product Pipeline - The company has a clear product pipeline, with multiple products in late-stage clinical trials, including the human diploid rabies vaccine and various influenza vaccines [30][31]. - The company achieved a 100% pass rate for vaccine product approvals in the first half of 2025, reinforcing its market leadership [27][30]. Strategic Initiatives - The company is actively exploring AI applications in vaccine research and has established a partnership to create an "AI + Vaccine Research Joint Laboratory" [34]. - The management is focused on industry integration and external acquisition opportunities to enhance growth [2][33].